This company has been marked as potentially delisted and may not be actively trading. Conatus Pharmaceuticals (CNAT) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock CNAT vs. OGEN, CMND, ADIL, CNSP, SONN, CANF, QNRX, MBIO, GLTO, and SBFMShould you be buying Conatus Pharmaceuticals stock or one of its competitors? The main competitors of Conatus Pharmaceuticals include Oragenics (OGEN), Clearmind Medicine (CMND), Adial Pharmaceuticals (ADIL), CNS Pharmaceuticals (CNSP), Sonnet BioTherapeutics (SONN), Can-Fite BioPharma (CANF), Quoin Pharmaceuticals (QNRX), Mustang Bio (MBIO), Galecto (GLTO), and Sunshine Biopharma (SBFM). These companies are all part of the "medical" sector. Conatus Pharmaceuticals vs. Oragenics Clearmind Medicine Adial Pharmaceuticals CNS Pharmaceuticals Sonnet BioTherapeutics Can-Fite BioPharma Quoin Pharmaceuticals Mustang Bio Galecto Sunshine Biopharma Oragenics (NYSE:OGEN) and Conatus Pharmaceuticals (NASDAQ:CNAT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, community ranking, valuation, analyst recommendations, risk and dividends. Which has more risk & volatility, OGEN or CNAT? Oragenics has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Comparatively, Conatus Pharmaceuticals has a beta of 1.84, meaning that its share price is 84% more volatile than the S&P 500. Does the MarketBeat Community prefer OGEN or CNAT? Conatus Pharmaceuticals received 537 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 79.67% of users gave Conatus Pharmaceuticals an outperform vote while only 0.00% of users gave Oragenics an outperform vote. CompanyUnderperformOutperformOragenicsOutperform VotesNo VotesUnderperform Votes55100.00% Conatus PharmaceuticalsOutperform Votes53779.67% Underperform Votes13720.33% Do insiders & institutionals have more ownership in OGEN or CNAT? 18.7% of Oragenics shares are owned by institutional investors. Comparatively, 15.2% of Conatus Pharmaceuticals shares are owned by institutional investors. 4.9% of Oragenics shares are owned by insiders. Comparatively, 11.3% of Conatus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is OGEN or CNAT more profitable? Oragenics has a net margin of 0.00% compared to Conatus Pharmaceuticals' net margin of -52.42%. Conatus Pharmaceuticals' return on equity of -48.22% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets OragenicsN/A -2,087.95% -486.56% Conatus Pharmaceuticals -52.42%-48.22%-39.32% Which has better earnings & valuation, OGEN or CNAT? Conatus Pharmaceuticals has higher revenue and earnings than Oragenics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOragenics$40K103.08-$20.66M-$1.12-0.17Conatus Pharmaceuticals$21.72M0.05-$11.39MN/AN/A Does the media refer more to OGEN or CNAT? In the previous week, Oragenics had 3 more articles in the media than Conatus Pharmaceuticals. MarketBeat recorded 3 mentions for Oragenics and 0 mentions for Conatus Pharmaceuticals. Oragenics' average media sentiment score of 0.17 beat Conatus Pharmaceuticals' score of 0.00 indicating that Oragenics is being referred to more favorably in the media. Company Overall Sentiment Oragenics Neutral Conatus Pharmaceuticals Neutral SummaryConatus Pharmaceuticals beats Oragenics on 8 of the 14 factors compared between the two stocks. Get Conatus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNAT vs. The Competition Export to ExcelMetricConatus PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.03M$6.48B$5.35B$8.38BDividend YieldN/A2.66%5.22%4.10%P/E Ratio-0.108.9226.8419.71Price / Sales0.05250.96391.39116.98Price / CashN/A65.8538.2534.62Price / Book0.066.466.794.50Net Income-$11.39M$143.98M$3.23B$248.18M Conatus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNATConatus PharmaceuticalsN/A$0.03flatN/A-85.2%$1.03M$21.72M-0.1030OGENOragenicsN/A$0.20+8.9%N/A-93.5%$4.21M$40,000.00-0.035Gap UpCMNDClearmind Medicine0.1301 of 5 stars$0.98-0.8%N/A-12.5%$4.18MN/A-0.52N/AADILAdial Pharmaceuticals3.2886 of 5 stars$0.63+3.8%$8.00+1,161.8%-51.6%$4.17MN/A-0.1920Earnings ReportAnalyst RevisionGap UpCNSPCNS Pharmaceuticals1.3008 of 5 stars$1.36+12.4%$25.00+1,738.2%-99.8%$4.00MN/A-0.025Earnings ReportHigh Trading VolumeSONNSonnet BioTherapeutics2.0631 of 5 stars$1.29-3.0%$20.00+1,450.4%-25.3%$3.96M$1M0.0010CANFCan-Fite BioPharmaN/A$1.09-0.9%$14.00+1,184.4%-57.2%$3.86M$674,000.00-0.618Gap DownQNRXQuoin Pharmaceuticals0.3415 of 5 stars$6.36+3.9%N/A-68.4%$3.74MN/A-1.574MBIOMustang Bio0.4903 of 5 stars$1.12-0.9%N/A-92.6%$3.70MN/A-0.01100Positive NewsEarnings ReportGLTOGalecto1.6576 of 5 stars$2.79+0.7%$10.00+258.4%-80.7%$3.69MN/A-0.1540SBFMSunshine Biopharma1.8709 of 5 stars$1.36+0.7%$15.00+1,002.9%+52.6%$3.68M$34.87M-0.013Earnings ReportGap Down Related Companies and Tools Related Companies Oragenics Competitors Clearmind Medicine Competitors Adial Pharmaceuticals Competitors CNS Pharmaceuticals Competitors Sonnet BioTherapeutics Competitors Can-Fite BioPharma Competitors Quoin Pharmaceuticals Competitors Mustang Bio Competitors Galecto Competitors Sunshine Biopharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNAT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conatus Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Conatus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNAT Stock Free CNAT Stock Alerts